Verona Pharma To Host Investor & Analyst R&D Forum On October 12, 2018
September 27 2018 - 2:00AM
UK Regulatory
TIDMVRP
LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for respiratory diseases, announces that management
will host an investor and analyst R&D forum on Friday, October 12 from
11 a.m. EDT to 2 p.m. EDT. The event will provide insights into the
unmet medical need and the challenges of treating chronic obstructive
pulmonary disease ("COPD"), as well as an update of the most recent
clinical data on RPL554, a first-in-class dual PDE3/4 inhibitor in late
stage clinical development for this indication. The forum will feature a
panel of physicians and scientists in the field of COPD to provide a
clinical perspective, as well as a representative from the COPD
Foundation to provide the patient perspective.
Attendance at this event is by invitation only. For additional details,
please contact Stephanie Carrington at
https://www.globenewswire.com/Tracker?data=5l-4CVM5hHGGoejSns9Fhi2sQvWVfAJw5OnhL349J1L7aKZyzLBgX4lE7CX3v7YnjiEUDGLne48r5HeHsRzaw_2DRCGj6izrEfON6hqd0XsKpHxMmxqadEor_pHo8Hig
stephanie.carrington@icrinc.com. A live webcast can be accessed on the
Investor Relations section of the Verona Pharma website at
https://www.globenewswire.com/Tracker?data=WL8I-N9ZQ-4C5-_ux_Ixl-TG5cQ3dMcAKoBmu8gORWuxjfkZWAV6DZscArTMXV2U-PySWKFW7h_bNNBq5dfUzYkUBYb1Sr_BalodNnEwYcGiurRTGiC44CQxaqd6X07G
http://investors.veronapharma.com/ and will be available for replay
until November 9, 2018.
About Verona Pharma plc and RPL554
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a
bronchodilator and an anti-inflammatory agent in a single compound. In
previous clinical trials, RPL554 has been observed to result in
bronchodilator effects when used alone or as an add-on treatment to
other COPD bronchodilators. It has shown clinically meaningful and
statistically significant improvements in lung function when
administered in addition to frequently used short- and long-acting
bronchodilators, such as tiotropium (Spiriva(R)), compared with such
bronchodilators administered as a single agent. RPL554 improved FEV(1)
over four weeks in patients with moderate-to-severe COPD when compared
to placebo and improved COPD symptoms and Quality of Life in a Phase 2b
multicenter European study performed in 403 patients. In addition,
RPL554 has shown anti-inflammatory effects in a standard challenge study
with COPD-like inflammation in human subjects. RPL554 has been well
tolerated in these studies and has a favorable safety and tolerability
profile, having been administered to more than 730 subjects in 12
clinical trials. Verona Pharma is developing RPL554 for the treatment of
COPD, cystic fibrosis ("CF"), and potentially asthma.
About COPD
Chronic obstructive pulmonary disease is a progressive and
life-threatening respiratory disease for which there is no cure.(1)
Although COPD is thought to be underdiagnosed, globally, around 384
million people suffer from the disease.(2) This number, according to the
World Health Organization ("WHO"), is likely to increase in coming years,
with estimates that COPD will become the third leading cause of death
worldwide by 2030.(1,3) The condition damages the airways and the lungs,
leading to persistent symptoms of breathlessness, impacting a person's
daily life and their ability to perform simple activities such as
walking up a short flight of stairs or carrying a suitcase.(1) Many
experience acute periods of worsening symptoms called 'exacerbations',
often leading to emergency department visits or hospital admissions and
are also associated with high mortality.(4) In the United States alone,
the 2010 total annual medical costs related to COPD were estimated to be
$32 billion and are projected to rise to $49 billion in 2020.(5) About
30-40% of moderate to severe COPD patients on triple inhaled therapy
(ICS/LAMA/LABA) remain uncontrolled and continue to experience airway
obstruction (breathing difficulties), COPD symptoms and
exacerbations.(6) There is an urgent need for drugs with novel
mechanisms of action that can be used by these patients in addition to
current therapies.
Forward-Looking Statements
This press release and the proposed investor and analyst R&D forum
contain forward-looking statements. All statements contained in this
press release and the forum that do not relate to matters of historical
fact should be considered forward-looking statements, including, but not
limited to, statements regarding the unmet medical need and the
challenges of treating COPD and the potential of RPL554 as a promising
first-in-class treatment option for COPD.
These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from our expectations expressed or implied by
the forward-looking statements, including, but not limited to, the
following: our limited operating history; our need for additional
funding to complete development and commercialization of RPL554, which
may not be available and which may force us to delay, reduce or
eliminate our development or commercialization efforts; the reliance of
our business on the success of RPL554, our only product candidate under
development; economic, political, regulatory and other risks involved
with international operations; the lengthy and expensive process of
clinical drug development, which has an uncertain outcome; serious
adverse, undesirable or unacceptable side effects associated with
RPL554, which could adversely affect our ability to develop or
commercialize RPL554; we may not be successful in developing RPL554 for
multiple indications; our ability to obtain regulatory approvals
necessary to conduct later stage trials and to commercialize RPL554 in
multiple major pharmaceutical markets; misconduct or other improper
activities by our employees, consultants, principal investigators, and
third-party service providers; material differences between our
"top-line" data and final data; our reliance on third parties, including
clinical investigators, manufacturers and suppliers, and the risks
related to these parties' ability to successfully develop and
commercialize RPL554; and lawsuits related to patents covering RPL554
and the potential for our patents to be found invalid or unenforceable.
These and other important factors under the caption "Risk Factors" in
our Annual Report on Form 20-F filed with the Securities and Exchange
Commission ("SEC") on February 27, 2018 relating to our Registration
Statement on Form F-1, and our other reports filed with the SEC, could
cause actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of the
date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim any
obligation to do so, even if subsequent events cause our views to
change. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this
press release.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
_________________________
(1) World Health Organization. Chronic Obstructive Pulmonary Disease.
https://www.globenewswire.com/Tracker?data=WL8I-N9ZQ-4C5-_ux_Ixl2wR0YCGo1ZDejIYzY_qG6rd9Sj2gGb2JLNLmidU-ZMSsHZZkKArLG7v-SCOIOmLrkTeKjC_XgNdEeHQYuqejtlq2pdzCj2rajqnyDNOe8OoEB3hjhRAqeWTvraFdj2TbBGEkrax09QQ6ET7bc5bVDA=
http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed September
2017.
(2) Adeloye D, Chua S, et al. Global and regional estimates of COPD
prevalence: Systematic review and meta--analysis. J Glob Health 2015;
5(2): 020415.
(3) World Health Organization. Burden of COPD.
https://www.globenewswire.com/Tracker?data=WL8I-N9ZQ-4C5-_ux_Ixl7-f5yCbOI5G0SgqaCu2chuqOe__LHbaxw3Zj75aBr9W0u0EFFSSuS_wyHgimVkNQLhcESfVh0Gw-jqAgbyIgyH8yn9S4O7-TiBnOR4eZaNaCb4VQarBXaqLQJRJOU9q09BkxD-BYs6_vtAqq8qv0To=
http://www.who.int/respiratory/copd/burden/en/. Accessed September 2017.
(4) COPD Foundations. Characteristics of COPD Patients Using United
States Emergency Care or Hospitalization.
https://www.globenewswire.com/Tracker?data=6KTvf22IEOJkbMagsA6j0Okx3gmHqjoZqQlgq1YP6crtSA6-KHn3DCinrwDImLNHWi8u5--wPLoDzTGsC4nAfOL8ipAdcuAAEw_YaS5JpGzEIKn54InNmjqotu8-7Lg9wyhDKZB6QL5V6sk0Eufvy9c5_o5S4rNmnFrYNTD1__1B0J5v_1pby1CDXY3RywTq-FzXGvsx3kyT4BLvQxMR6O_qMj_d_Wgb1RhW6u1huad2EjgWBp-FXooWLyS2EZNHPZoCEzUnubb6hZejSh26Gs51X4DlNumMlHQ2zX6yLmsQcPpfR0FPpiYO8MShsgPFlOUtlXePwn1lELYiblXGWCJLTMOFCFTrQ4pLgU0z_oIG5fpcRrmZux36F3s4PLQoHC2Teqqkml6lnIoWte3pGQ==
https://journal.copdfoundation.org/jcopdf/id/1103/Characteristics-of-COPD-Patients-Using-United-States-Emergency-Care-or-Hospitalization.
Accessed September 2017.
(5) Center for Disease Control. Increase Expected in Medical Costs for
COPD.
https://www.globenewswire.com/Tracker?data=6KTvf22IEOJkbMagsA6j0E5aSbVEE--tSH5I9U3dlNo_uzaMbwYRSFW2pOO0fBBYfEgY_1NrTmpttks87wMEIhQ34bREG2OCLRt2laWF8xUjuKRZYoC7HhQ5vken88zS4qI0Y4J5cmf0ZE85bZQJsQ==
https://www.cdc.gov/features/ds-copd-costs/. Accessed September 2017.
(6) Mullerova H., et al., Characterization of COPD Patients Treated With
Inhaled Triple Therapy Containing Inhaled Corticosteroid [ICS],
Long-Acting Beta2-Agonists [LABA], and Long-Acting Muscarinic
Antagonists [LAMA] in the UK, American Journal of Respiratory and
Critical Care Medicine 2017;195:A4986
(6) Vestbo J, et al., Single inhaler extrafine triple therapy versus
long-acting muscarinic antagonist therapy for chronic obstructive
pulmonary disease (TRINTY); a double-blind, parallel group, randomised
controlled trial, The Lancet, Vol 389, p. 1919-1929; May 13, 2017.
(END) Dow Jones Newswires
September 27, 2018 02:00 ET (06:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024